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Abstract
Recently developed drugs and innovative strategies for the treatment of chronic infection with
genotype 1 hepatitis C virus (HCV) have become the standard of care. The protease inhibitors
telaprevir (Incivek) and boceprevir (Victrelis) are the first direct-acting antiviral (DAA) agents
approved, and many more are being developed. These drugs substantially increased rates of
sustained virologic response in treatment-naïve and -experienced patients, in conjunction with
peginterferon and ribavirin (triple therapy), in phase 3 trials. The efficacy of triple therapy
depends on appropriate selection of patients, although the population of patients that receive triple
therapy could be expanded as the risk/benefit ratio improves. Attention to details that reflect the
standard of care, such as appropriate dosing, anticipation of adverse effects, and strict adherence to
stopping rules, will insure the success of these drugs and lead the way for new combination
therapies.
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In 2011, great advances were made in the treatment of chronic infection with genotype 1
hepatitis C virus (HCV). Gastroenterologists and hepatologists now treat these patients with
the immunomodulator peginterferon (PEG-IFN) and ribavirin (RBV), combined with
directacting antiviral (DAA) agents. Telaprevir (Incivek; Vertex Pharmaceuticals, Inc,
Cambridge, MA) and boceprevir (Victrelis; Merck & Co, Inc, Whitehouse Station, NJ) are
nonstructural serine (NS3/4) protease inhibitors and the first DAAs approved for use in the
United States and European Union, although many others are in the pipeline. The
combination of DAAs, PEG-IFN, and RBV (triple therapy) substantially increases the rate
of sustained virologic response (SVR) in treatment-naïve and –experienced patients.
Boceprevir and telaprevir stop HCV replication by inhibiting the NS3/4 protease, which is
required for processing of the HCV polyprotein. These agents mimic the carboxy-terminal
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end of the NS3 protease and thereby interfere with formation of the HCV polyprotein, which
blocks HCV replication.1 Although protease inhibitors are potent antiviral agents, they must
be given in combination with PEG-IFN and RBV to prevent the rapid selection of resistant
variants.2–4 Studies have shown that removal of RBV from the treatment regimen
compromises efficacy, increasing the rate of virologic breakthrough.5 Optimizing the rates
of SVR to these drugs requires strategies to promote appropriate use and to avoid misuse of
these drugs.
Triple Therapy Increases Rates of SVR for All Populations
Five distinct phase 3 trials have been performed with boceprevir and telaprevir (Table 1).
For treatment-naïve patients, the serine protease inhibitor therapy-2 (SPRINT-2)6 trial
examined the effects of PEG-IFN α-2b, RBV, and boceprevir, whereas the A new direction
in HCV care: astudy of treatment naïve hepatitis c patient with telaprevir (ADVANCE)7 and
illustrating the effects of combinatherapy with telaprevir (ILLUMINATE)8 studies
investigated the effects of PEG-IFN α-2a, RBV, and telaprevir. Treatment-experienced
patients were included in retreatment with HCV serine protease inhibitor boceprevir and
pegIntron/rebetol-2 (RESPOND-2) study,9 in which they received boceprevir, and in the
retreatment of patients with telaprevir based regimen to optimize outcomes (REALIZE)
study,10 in which they received telaprevir. Each trial reported improved efficacy compared
with the standard of care (SOC) and demonstrated the opportunity to increase rates of curing
HCV infection and shortening the duration of therapy for selected patients.
SPRINT-2 included separate cohorts of black and non-black patients and had a 4-week lead-
in phase, in which patients were given PEG-IFN α-2b and RBV before triple therapy was
initiated with boceprevir. Patients were randomly assigned to groups given either the SOC
(48 weeks of PEG-IFN α-2b and RBV), boceprevir for 44 weeks with a fixed duration of
PEG-IFN α-2b and RBV, or response-guided therapy (RGT), in which they received 24
weeks of boceprevir in a total treatment duration of 28 weeks. Patients who received RGT
and had an undetectable level of HCV RNA at weeks 8 and 24 received no further therapy.
If HCV RNA was detected, they received PEG-IFN α-2b and RBV, plus a placebo, for an
additional 20 weeks (total treatment duration of 48 weeks). In the non-black patients cohort,
patients in the fixed duration treatment group had an SVR rate of 68%, comparable with
those who received RGT (67%), whereas the SVR rate in the control arm was only 40%.
The rates of SVR following treatment with boceprevir were lower in the black than in the
non-black patients cohort; there was a numerical but not statistically significant difference
between the groups that received RGT and those that received 48 weeks of treatment,
possibly because of the small number of patients in the black patients cohort (Table 1).
The ADVANCE and ILLUMINATE studies investigated triple therapy with a combination
of telaprevir, PEG-IFN α-2a, and RBV (Table 1). Patients in the ADVANCE trial were
randomly assigned to groups given 12 weeks of triple therapy, 8 weeks of triple therapy, or
the SOC. Patients who received triple therapy continued PEG-IFN α-2a and RBV for a
minimum duration of 24 weeks, whereas therapy was stopped for patients with extended
rapid virologic responses (eRVRs; undetectable levels of HCV RNA at weeks 4 and 12). All
others continued to receive PEG-IFN and RBV through week 48. Patients treated with 12
weeks or 8 weeks of telaprevir had significantly higher rates of SVR (75% and 69%,
respectively) than the SOC group (44%).7
The ILLUMINATE study was designed to confirm that shortened treatment duration, based
on response-guided principles, was not inferior to fixed treatment duration for patients who
achieved eRVRs. All patients were initially treated with triple therapy that included
telaprevir. Those achieving eRVRs were randomly assigned to groups that were given 12 or
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36 additional weeks of PEG-IFN and RBV (total treatment duration of 24 weeks or 48
weeks). Among patients who achieved an eRVR (65%), the rates of SVR were similar after
24 or 48 weeks of therapy (92% and 88%, respectively). Therapy can therefore be shortened
for a substantial number of patients, without compromising efficacy.8
Triple therapy substantially improves outcomes for patients previously treated with only
PEG-IFN and RBV. The RESPOND-2 trial focused on treatment-experienced patients, who
were given triple therapy with boceprevir (Table 1). This trial included prior partial
responders (patients with a ≥2log decline in HCV RNA by week 12 of treatment with PEG-
IFN and RBV, but with detectable levels of HCV RNA throughout the course of treatment)
and relapsers (patients with undetectable levels of HCV RNA during therapy but did not
attain an SVR). Patients who did not have a ≥2log reduction in HCV RNA (prior null
responders) were excluded. As with all boceprevir studies, RESPOND-2 included a 4-week
lead-in phase of PEG-IFN and RBV therapy, followed by triple therapy for a fixed duration
of 44 weeks (total treatment duration of 48 weeks). The study included a group that received
RGT, in which patients with undetectable levels of HCV RNA at weeks 8 and 24 continued
triple therapy for only 32 weeks (total treatment duration of 36 weeks). Prior partial
responders had SVR rates of 52% for those who received 48 weeks of therapy, 40% for
those who received RGT, and 7% in the SOC arm. As anticipated, prior relapsers had
substantially greater rates of SVR than the partial responders (75%, 69%, and 29% for the 3
treatment regimens, respectively).9
The study of telaprevir in treatment-experienced patients (REALIZE) included prior null
responders, partial responders, and relapsers. Participants were treated with the SOC or a
fixed duration of triple therapy (12 weeks), followed by PEG-IFN and RBV through week
48. One group received a 4-week lead-in with PEG-IFN and RBV before triple therapy.
However, because no difference in response was observed (lead-in vs no lead-in), results
from these telaprevir-treated groups were combined. The rates of SVR in the SOC and triple
therapy groups, respectively, were 5% and 31% among prior null responders, 15% and 57%
among prior partial responders, and 24% and 86% among prior relapsers (Table 1).10
The phase 3 programs for boceprevir and telaprevir have provided many important insights
into the opportunities and limitations of triple therapy for diverse populations.
• Treatment-naïve and -experienced patients benefit from triple therapy.
• Half to two-thirds of treatment-naïve patients given boceprevir and telaprevir can
have reduced duration of treatment, without compromising efficacy.
• Among treatment-experienced patients, prior relapsers have the best response,
whereas less than one-third of prior null responders have an SVR.
• Certain populations, such as patients with advanced fibrosis or cirrhosis, have
lower rates of SVR even when using triple therapy—response-guided regimens are
not recommended.
• Telaprevir and boceprevir have adverse effects that pose challenges for patients and
providers.
Initiating Triple Therapy
Patients with HCV genotype 1 infections are potential candidates for triple therapy regimens
that include boceprevir or telaprevir provided they have no contraindications to PEG-IFN
and RBV, which remain the backbone of therapy. When determining which of these patients
should receive therapy, health care professionals can consider treating a broader population
of patients (eg, those with milder disease, stage 0–1 fibrosis) that might have had treatment
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delayed in the past. Now that rates of SVR approach 70% among treatment-naïve patients,
and a shorter duration of therapy is possible for most, the risk/benefit ratio could lead to
earlier treatment of many patients.
However, concerns about adverse events from PEG-IFN–based regimens remain a deterrent
for some patients and providers. Additionally, many patients might ask whether they truly
need triple therapy. Patients with the CC polymorphism of interleukin 28b (IL28B),
associated with increased response to therapy, should achieve rates of SVR on dual therapy
comparable with those of triple therapy, although no randomized clinical trials have been
performed to test this assertion.11 Furthermore, the superior SVR rates of patients with the
CC polymorphism reflect 48-week regimens of dual therapy; these same patients are likely
to have a shortened duration of therapy if they take 3 drugs. Boceprevir and telaprevir have
shown activity against other HCV genotypes, although the clinical data are too limited for
recommendation of their routine use in patients with HCV non-1 genotype infections. 12–14
Once the decision has been made to begin triple therapy, clinicians should emphasize the
importance of proper administration of the drugs to maximize the chance for an SVR and to
minimize viral resistance to these and future DAAs.
Telaprevir is manufactured as a 375-mg tablet that is dosed as 2 pills, 3 times a day, 7–9
hours apart, with food; boceprevir is prepared as 200-mg capsules and dosed as 4 capsules
(800 mg), 3 times a day, 7–9 hours apart, with food (Table 2). Boceprevir and telaprevir
must be administered only in combination with PEG-IFN and RBV to minimize and prevent
viral resistance.15 If the protease inhibitors are given as monotherapy, viral resistance will
develop within several days to 2 weeks and severely compromise the efficacy of these and
other drugs in this class. The importance of adherence to all the drugs in the triple therapy
regimen must be fully explained, and potential barriers to adherence should be addressed
with each patient before therapy begins.
Evaluating Drug Interactions
Before treating patients with protease inhibitors, clinicians must review all the medications
used by their patients to avoid potentially harmful drug interactions. Boceprevir and
telaprevir are each metabolized via the cytochrome p450 pathway, along with many other
common medications.16,17 These drugs also inhibit and/or serve as substrates for p-
glycoprotein.17 Administration of boceprevir and telaprevir could therefore alter plasma
concentrations of the other drugs that are metabolized by this pathway (or those drugs could
alter the concentrations of boceprevir and telaprevir) affecting efficacy or increasing
toxicities.16,17
For this reason, there are a number of drugs that are contraindicated for use with boceprevir
and telaprevir (Table 3). Certain drugs could be given at reduced doses to patients who are
taking protease inhibitors or used with careful monitoring of therapeutic dose and efficacy.
Systemic hormonal therapies might not be as effective in women who take these protease
inhibitors: 2 additional methods of birth control, such as barrier contraception and an
intrauterine device, should be used in women of child-bearing age.16,17 Boceprevir and
telaprevir could also affect metabolism of cholesterol-lowering agents (statins) and
antidepressant medications such as escitalopram. Users of statins might take a break from
therapy while taking a protease inhibitor: once the triple therapy phase is complete, patients
can safely resume use of these drugs. Levels of escitalopram can decrease during telaprevir
therapy, so the dose of escitalopram might have to be modified to maintain its therapeutic
effects. The product information brochures for boceprevir and telaprevir provide guidance
about drug interactions, and many on-line resources (such as www.hcvadvocate. org and
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www.hep-druginteractions.org, among others) are available to assist clinicians with
management.
Monitoring Levels of HCV RNA and Adherence to Treatment Algorithms
The telaprevir treatment algorithm for treatment-naïve patients and prior relapsers is shown
in Figure 1A. These patients could be eligible for RGT with telaprevir. Patients begin taking
PEG-IFN, RBV, and telaprevir (750 mg, 3 times a day, 7–9 hours apart) concurrently. The
importance of the dosing interval for telaprevir should be emphasized to patients. The 7–9
hour window is important for drug pharmokinetics and for timing with meals. Telaprevir
absorption is increased by 237% when taken with a standard-fat meal (~500 calories, 20 g
fat), compared with no food. It should be administered within 30 minutes of a meal or snack
that has at least 20 g of fat.16
Levels of HCV RNA should be checked 4 and 12 weeks after therapy begins to determine
whether patients are eligible for RGT. Those who have an undetectable level of virus at
weeks 4 and 12 (an eRVR) can be considered for 24 weeks of total therapy and only need an
additional 12 weeks of treatment with PEG-IFN and RBV. Without an eRVR, an additional
36 weeks of PEG-IFN and RBV are recommended for a total of 48 weeks of therapy. A
shortened duration of treatment is not recommended for prior partial and null responders:
these patients should complete 12 weeks of treatment with PEG-IFN, RBV, and telaprevir,
and then receive 36 more weeks of PEG-IFN and RBV, for a total of 48 weeks of therapy
(Figure 1).16
In contrast to telaprevir, combination therapy with boceprevir begins with a 4-week lead-in
phase of only PEG-IFN and RBV. Boceprevir is added at week 4, and triple therapy is
continued through at least week 28. The drug is taken at the same interval (3 times a day, 7–
9 hours apart), and plasma levels are increased by 65% when the drug is taken with food
compared with a fasting state. Bioavailability, however, does not vary with type of meal
(high fat or low fat).17 Patients who are treatment naïve and have undetectable levels of
HCV RNA at weeks 8 and 24 qualify for RGT, and treatment can be stopped at week 28.
Those patients with detectable levels of HCV RNA at week 8 but undetectable levels at
week 24 should continue to take all 3 drugs through week 36 and then continue to take PEG-
IFN and RBV through week 48 (Figure 1B).
Prior partial responders and relapsers are also given a 4-week lead-in phase with PEG-IFN
and RBV and then start taking boceprevir at week 4. Levels of HCV RNA are measured at
weeks 8 and 24. Patients who have undetectable levels of HCV RNA at both time points
should continue triple therapy through week 36, and then all drugs may be stopped. For
those who have detectable HCV RNA at week 8 but not week 24, triple therapy should be
continued through week 36 followed by PEGIFN and RBV through week 48 (Figure 1).17
HCV has a rapid but imperfect replication process, so quasispecies and resistant variants
exist in treatment-naïve patients18 and are selected for in patients with suboptimal responses
to therapy. Commercial tests for resistant variants are available but are not generally
recommended because results will not alter decisions about current therapy. If triple therapy
does not work, this must be recognized at an early stage to minimize development of
resistant variants. Guidelines for discontinuing therapy should be followed (Figure 1).
Patients treated with telaprevir who have a viral load >1000 IU/mL at week 4 should stop
taking all 3 drugs. At week 12 (when telaprevir is finished), a viral load >1000 IU/mL also
mandates cessation of PEG-IFN and RBV treatment. Futility of boceprevir-based triple
therapy is defined as a level of HCV RNA ≥100 IU/mL at week 12 or any detectable HCV
RNA at week 24. If either of these conditions are met, treatment should be stopped (Figure
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1).17 Detection of virus at week 24 also indicates treatment failure, and PEG-IFN and RBV
therapy should be stopped.16
Strict adherence to the treatment guidelines is essential for optimal outcome, so patients
should be advised to use pill boxes, timers, and premade meals and snacks. Patients also
benefit from an educational session before therapy begins to address these issues. Regular
clinic visits are required to manage adverse events and monitor adherence.
Response-Guided Treatment Based on Level of HCV RNA
Assays for HCV RNA vary in their lower limit of quantification (LLQ; the lowest level of
virus for which quantification is considered accurate) and in the actual limit of detection
(LOD; the lowest level at which the presence of analyte in a sample of HCV RNA can be
detected in serum or plasma).19 A post hoc analysis by the US Food and Drug
Administration found that rates of SVR were reduced by approximately 20% when therapy
was shortened for patients with levels of HCV RNA below the LLQ but above the LOD
(indicating a low level of residual viremia).20,21
In trials of protease inhibitors, HCV RNA was measured using Roche COBAS Taqman Test
v.2 with the high pure system. The LLQ for this test is 25 IU/mL, and the LOD was 9.3 IU/
mL.16,17 A patient with a value between these levels might be reported as having HCV RNA
that is less than 25 IU/mL but detectable. This finding indicates that the virus is still present
and should not be considered undetectable16,17 for the purpose of applying RGT of
shortened duration. Clinicians and laboratory managers should ensure that the characteristics
of their HCV RNA assay meet or exceed those of assays used in the clinical trials and report
the results in a manner most useful to clinicians, who make treatment decisions based on this
information.
Identification and Management of Adverse Events
Anticipating the adverse effects of telaprevir and boceprevir, informing patients about their
risk, and being prepared to manage them is important for safe and successful outcomes from
triple therapy. Adverse events from PEG-IFN and RBV therapy are well established and still
account for most adverse effects associated with triple therapy.16,17 However, certain
adverse effects can be exacerbated, and new adverse events can occur with these regimens
(Table 4). In the phase 3 trials for telaprevir, some of the most significant adverse effects
were rash (56%), anemia (36%), and anorectal complaints (29% in aggregate).7,8,10,16 The
most significant adverse effects in the phase 3 trials of boceprevir were anemia (45%–50%)
and dysgeusia (35%–44%).6,9,17
Anemia
Anemia is an adverse effect of telaprevir- and boceprevir- based triple therapy
(Supplementary Table 1). The severity of anemia reported in clinical trials was additive to
that expected from RBV. Hemoglobin levels decreased approximately 1 g more than with
PEG-IFN and RBV but returned to expected levels once telaprevir or boceprevir were
discontinued. In trials of telaprevir, anemia was managed by reducing the dose of only RBV,
whereas, in trials of boceprevir, erythropoietic growth factors were given to 43% of
participants compared with 24% of the patients receiving only PEG-IFN and RBV.6,9,17
Among patients given either drug, anemia was initially managed by regular monitoring
(every 2 weeks) and reducing the dose of RBV. In practice, the dose of RBV should be
lowered when hemoglobin decreases by 1.5 g/dL within a 2-week period22 to pre-empt
severe anemia and discontinuation of RBV. Fortunately, SVR rates are not reduced when the
dose of RBV is reduced.23 Patients with severe (persistently ≤10 g/dL), symptomatic, or
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progressive anemia, despite a reduced dose of RBV, can be given growth factors such as
epoeitin-α. It is important to note that doses of protease inhibitors cannot be reduced: they
are used in an all or none manner. If the anemia becomes severe enough to require cessation
of RBV, telaprevir must be stopped as well.16 Additionally, if IFN-related adverse effects
prompt its discontinuation, all drugs must be stopped.
Rash
Management of a telaprevir-associated rash begins with an assessment of its severity. Mild
rashes are localized or have a limited distribution and appear with or without pruritus.
Patients with these adverse effects can be given an oral antihistamine and a topical
corticosteroid, if necessary. Importantly, all drugs for treatment of HCV should be
continued. Moderate rashes are diffuse and can have some peeling skin, pruritus, or
involvement of mucous membranes, without ulceration. These rashes should also be treated
with oral antihistamines and topical corticosteroids. All HCV therapies can be continued
with close observation. It is a challenge to differentiate mild-moderate rashes caused by
telaprevir from those caused by RBV.
Severe skin rashes are generalized; involve more than 50% of the body surface; and can
present with vesicles, bullae, or ulcerations. For patients with severe rash, telaprevir therapy
should be stopped, but treatment with PEG-IFN and RBV can be continued. If the rash does
not improve after 7 days, or gets worse, all drugs should be stopped, and a dermatologist can
be consulted. Only 5%–7% of patients in clinical trials stopped taking telaprevir because of
rash.7,8,10,16 The dose of telaprevir should not be reduced, and, once stopped, therapy should
not be reinitiated. Serious cutaneous adverse reactions, such as Stevens–Johnson syndrome r
drug rash with eosinophillia and systemic symptoms, such as fever or edema (also known as
DRESS), are extremely rare. If suspected, urgent medical evaluation and cessation of all
treatment are indicated.16
Gastrointestinal Adverse Effects
The anorectal complains associated with telaprevir therapy include hemorrhoids, anal
puritis, anorectal discomfort, and anal burning. In trials, most events were mild to moderate
in severity, and less than 1% led to discontinuation of telaprevir. These adverse effects can
usually be managed with topical corticosteroids or analgesics (eg, lidocaine).16 Over-the-
counter hemorrhoid preparations and antidiarrheal agents can also be used. Anorectal
symptoms resolve immediately when patients stop taking telaprevir.
Dysgeusia (altered taste sensations or unpleasant taste in the mouth) was the only
gastrointestinal symptom that occurred more often in patients given boceprevir than the
SOC. Patients are managed based on their symptoms, but no patients were reported to have
significant weight loss from dysgeusia.
Limitations of Triple Therapy Regimens for Certain Populations
Phase 3 trials demonstrated the overall efficacy of triple therapy with telaprevir or
boceprevir in patients with chronic hepatitis C. However, certain populations were either
underrepresented or not included in these studies, so there is uncertainty in the exact point
estimates of response.
African American Patients
African American patients were enrolled in the telaprevir and the boceprevir studies,
although not at a rate reflective of the HCV prevalence in the African American population.
In the phase 3 trial of boceprevir in treatment-naive patients (SPRINT-2), the groups that
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received boceprevir included 107 African American patients, within a separate cohort, and
more than 600 non-African American patients.6 Similarly, only about 9% of the population
treated with telaprevir triple therapy in the ADVANCE and ILLUMINATE trials was
African American. 7,8 Furthermore, among previously treated patients in the phase 3 trials of
boceprevir and telaprevir, only 79 were African American.9,10 Triple therapy with either
protease inhibitor substantially increased rates of SVR in African American patients,
compared with only PEG-IFN and RBV, although the rate of SVR was still lower than in
white thnicity populations.
Patients With Cirrhosis
In the phase 3 trials of telaprevir and boceprevir, approximately 8%–27% of participants had
advanced fibrosis or cirrhosis.6–10 Because of the small numbers of patients with advanced
disease, those with cirrhosis or bridging fibrosis were often analyzed together, limiting the
conclusions that could be made about either group. Patients with cirrhosis had significant
increases in rates of SVR with the addition of a protease inhibitor to therapy, although this
rate was still lower than that of patients with milder fibrosis. Cirrhotic patients treated for a
shorter time by response-guided criteria had a numerically lower rate of response than those
treated with a longer, fixed-duration regimen.6,8,9,16,17 These results led to the
recommendation that fixed-duration regimens (48 weeks of therapy) are most appropriate
for patients with cirrhosis to maximize their potential rate of SVR.16,17
For patients with cirrhosis, attaining an SVR can eliminate concerns about post-transplant
HCV or even obviate the need for liver transplant. However, there is no safety data on
treating patients with advanced liver disease beyond well-compensated disease (Childs–
Pugh A), so caution and careful patient selection are important. Triple therapy is not
approved for patients who have received liver transplants, and protease inhibitors have
significant interactions with drugs such as calcineurin inhibitors. Serum levels of tacrolimus
increase approximately 25% to 70% fold with concomitant administration of boceprevir or
telaprevir, respectively.24,25
Prior Null Responders
Treatment-experienced patients have better responses to triple therapy than to re-treatment
with PEGIFN and RBV. However, intrinsic IFN responsiveness directly correlates with
SVR in treatment-experienced (and naïve) patients. Response also correlated with IL28B
genotype, in retrospective analyses, although patients with the polymorphisms associated
with lack of response (CT and TT) also had substantial increases in rates of SVR to triple
therapy compared with PEG-IFN and RBV alone.26,27 The main risk of re-treating patients
with a low chance of treatment success is creating viral resistant populations, particularly in
those with poor interferon responsiveness. The long-term impact of these viral variants on
retreatment with second-generation protease inhibitors or even quadruple therapies that may
contain a protease inhibitor in the future remains unknown.
Studies of telaprevir and boceprevir demonstrated that partial responders had incremental
improvement in SVR, although there is a clear drop off in response compared with naïve
patients and relapsers.10 Prior null responders were the least likely to achieve SVR (31%)
with telaprevir triple therapy in the REALIZE study. The same relationships were evident in
the RESPOND-2 boceprevir study, particularly when the virologic response during the lead-
in phase was considered as a surrogate for the exclusion of prior null responders.9 Prior null
responders with cirrhosis pose the greatest challenge for treatment. Subgroup analysis of
REALIZE suggests only ~15% SVR in this population, although only a small number of
patients with these characteristics were included.10 The risk of selecting resistant variants to
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protease inhibitors may be too great when other drug options may be available in the future,
although decisions must be individualized for each patient.
Other Populations
There are limited data for the use of triple therapy in special populations, such as patients
with human immunodeficiency virus (HIV) or hepatitis B virus coinfection or those with
mental health issues. These populations were either underrepresented or excluded from
clinical trials. In deciding whether or not to give a patient triple therapy, clinicians should
consider whether the addition of a new drug to the treatment regimen has a greater chance of
helping or harming each individual patient. For patients coinfected with HIV and HCV,
interactions among drugs must be considered. Interactions between HCV and HIV protease
inhibitors are complex, as is management of hepatitis B virus coinfected patients.
Patients with mental health comorbidities might benefit from triple therapy, although there
are no data available from this specific population. However, now that SVR rates approach
70% and many patients require only 6 months of IFN exposure, antiviral therapy could be
possible for certain patients for whom a favorable benefit to risk profile exists. From a
public health perspective, broadening the scope of patients treated for HCV infection,
combined with the impact of increasing the rate of SVR, provides an opportunity to reduce
the future burden of cirrhosis, hepatocellular carcinoma, and end-stage liver disease.28,29
Future Directions and Preventing Resistance to New Drugs
Although there are many promising DAAs in development, it is important to remember that
decisions made in practice today could affect the success of future drugs. Current triple
therapy combinations will eventually be replaced by IFN-free regimens of protease
inhibitors, nucleoside/non nucleoside polymerase inhibitors, NS5A inhibitors, and other
classes of drugs.30
The effects of lack of response to triple therapy have recently been reviewed.31 Patients who
did not respond to telaprevir or boceprevir carried a dominant strain of protease inhibitor-
resistant virus that was present at the time of virus breakthrough or relapse, but the wild-type
strain reemerged as the dominant quasispecies many months after therapy.32–35 The
significance of these findings is unclear. The return of a wild-type population of HCV could
indicate that patients can be rechallenged at a later date, with a combination of drugs that
includes one of the first-generation protease inhibitors as has been shown in a small number
of patients re-treated with telaprevir-containing regimens after a brief exposure to the
protease inhibitor in clinical trials.36 However, it is also possible that the resistant
quasispecies will emerge again, once selective pressure is applied. If these patients respond
poorly to PEG-IFN RBV (especially those with the TT genotype of IL28B), viral resistance
will continue to be a problem until multitargeted DAAs are available.31,37
Summary
The NS3/4 protease inhibitors boceprevir and telaprevir are the first in a pipeline of new
therapies that will change treatment of HCV infection. Rates of SVR for patients with
genotype 1 HCV infection have increased to ~70%, and one-half to two-thirds of patients
will be eligible for a shortened duration of therapy. To take advantage of these
developments, clinicians must select appropriate patients for therapy, perhaps even
expanding the pool of patients treated, as the risk/benefit ratio for therapy improves. Once a
commitment to treatment has been made, appropriate dosing, monitoring for drug
interactions, anticipation of adverse effects, and strict adherence to stopping rules will
optimize responses to the new standard of care. Attention to these details will insure the
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success of these new drugs and preserve the promise of future generations of anti-HCV
therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding
Supported in part by a National Institutes of Health career development award (1KL2-RR025746-03; to A.S.B.) and
in part by the National Institutes of Health Mid-Career Mentoring Award (K24 DK066144; to M.W.F.).
Biographies
Abbreviations used in this paper
ADVANCE a new direction in HCV Care: a study of treatment naïve hepatitis C
patient with telaprevir
DAA direct-acting antiviral
eRVR extended rapid virologic response
HCV hepatitis C virus
HIV human immunodeficiency virus
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RBV ribavirin
REALIZE the retreatment of patients with telaprevir based regimen to
optioutcomes
RESPOND-2 retreatment with HCV serine protease inhibitor boceprevir and
pegintron/rebetol-2
RGT response-guided therapy
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SOC standard of care
SPRINT-2 serine protease inhibitor therapy-2
SVR sustained virologic response
References
1. Steinkuhler C, Biasiol G, Brunetti M, et al. Product inhibition of the hepatitis C virus NS3 protease.
Biochemistry. 1998; 37:8899–8905. [PubMed: 9636031]
2. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis
C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem. 2005; 280:36784–36791.
[PubMed: 16087668]
3. Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV)
RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease
inhibitor in vitro. Antimicrob Agents Chemother. 2005; 49:4305–4314. [PubMed: 16189112]
4. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic
changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132:1767–
1777. [PubMed: 17484874]
5. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for
chronic HCV infection. N Engl J Med. 2009; 360:1839–1850. [PubMed: 19403903]
6. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1
infection. N Engl J Med. 2011; 364:1195– 1206. [PubMed: 21449783]
7. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic
hepatitis C virus infection. N Engl J Med. 2011; 364:2405–2416. [PubMed: 21696307]
8. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for
hepatitis C virus infection. N Engl J Med. 2011; 365:1014–1024. [PubMed: 21916639]
9. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1
infection. N Engl J Med. 2011; 364:1207–1217. [PubMed: 21449784]
10. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med.
2011; 364:2417–2428. [PubMed: 21696308]
11. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-
induced viral clearance. Nature. 2009; 461:399–401. [PubMed: 19684573]
12. Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease
inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother.
2006; 50:1813–1822. [PubMed: 16641454]
13. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and
orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents
Chemother. 2006; 50:899–909. [PubMed: 16495249]
14. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin
reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Gastroenterology. 2011; 141:881–889, e1. [PubMed: 21699786]
15. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis
C virus infection: 2011 practice guideline by the American Association for the Study of Liver
Diseases. Hepatology. 2011; 54:1433–1444. [PubMed: 21898493]
16. Incivek. Package insert. Cambridge, MA: Vertex Pharmaceuticals Inc; 2011.
17. Victrelis. Package insert. Whitehouse Station, NJ: Merck and Co, Inc; 2011.
18. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with
decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008;
198:800–807. [PubMed: 18637752]
19. COBAS Taqman HCV Test v.2 for use with high pure system. CE-IVD package insert. Document
Rev 5.0 ed. Pleasanton, CA: Roche Molecular Diagnostics; 2010.
Barritt and Fried Page 11













20. Naeger, LK.; Harrington, PR. Effect of on-treatment undetectable or detectable/BLOQ HCV RNA
measurements on SVR rates in phase 3 clinical trials of boceprevir and telaprevir. Sixth
International Workshop on Hepatitis C—resistance and new compounds; Cambridge, MA: 2011.
21. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis
C virus RNA during boceprevir or telaprevir treatment. Hepatology. 2011 Nov 16. [Epub ahead of
print].
22. Reau N, Hadziyannis SJ, Messinger D, et al. Early predictors of anemia in patients with hepatitis C
genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008;
103:1981–1988. [PubMed: 18796095]
23. Poordad F, Sulkowski M, Reddy R, et al. Anemia had no effect on efficacy outcomes in treatment-
naive patients who received telaprevir- based regimen in the Advance and Illuminate phase 3
studies. Gastroenterology. 2011; 140:S898–S899.
24. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of
cyclosporine and tacrolimus. Hepatology. 2011; 54:20–27. [PubMed: 21618566]
25. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents: a
potentially lethal cocktail. Hepatology. 2011; 54:3–5. [PubMed: 21710471]
26. Younossi ZM, Aerssens J, Pol S, et al. Similar SVR rates in IL28B, CC, CT or TT prior relapser,
partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective
analysis of the Realize study. Gastroenterology. 2011; 140:S907–S908.
27. Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in
patients with hepatitis C genotype 1 treated with boceprevir (Boc) combination therapy.
Gastroenterology. 2011; 140:S941.
28. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the
United States: a multiple cohort model of HCV prevalence and disease progression.
Gastroenterology. 2010; 138:513–521. e1–e6. [PubMed: 19861128]
29. Bonner J, Barritt A, Fried M, et al. Time to rethink antiviral treatment for hepatitis C in patients
with coexisting mental health/ substance abuse issues. Chapel Hill, NC: University of North
Carolina. 2011
30. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is
resistance important? Liver Int. 2012; 32(Suppl 1):79–87. [PubMed: 22212577]
31. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis
C virus. Hepatology. 2011; 53:1742–1751. [PubMed: 21374691]
32. Kieffer TL, Bartels DJ, Sullivan J, et al. Clinical virology results from telaprevir phase 3 study
ADVANCE. Hepatology. 2010; 52:879A.
33. Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis
C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis
of the EXTEND study. Hepatology. 2010; 52:436A. [PubMed: 20683943]
34. Vierling JM, Ralston R, Lawitz EJ, et al. Long-term outcomes following combination treatment
with boceprevir plus peg-intron/ ribavirin (P/R) in patients with chronic hepatitis C, genotype 1
(CHC-G1). J Hepatol. 2010; 52:S470–S471.
35. Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations
within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin
Virol. 2011; 52:321–327. [PubMed: 21924672]
36. Sarrazin C, Reesink HW, Zeuzem S, et al. Retreatment with telaprevir/ PEG-IFN/RBV after a short
exposure to telaprevir in phase I studies: interim results from a phase IIIb rollover trial (C219).
Hepatology. 2011; 54:377A–378A. [PubMed: 21710476]
37. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C
genotype 1. N Engl J Med. 2012; 366:216–224. [PubMed: 22256805]
Barritt and Fried Page 12














Duration for telaprevir and boceprevir-based triple therapy, based on previous treatment.
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Table 2
Dosing and Monitoring Rules for Boceprevir and Telaprevir
Drug Dosing
Duration of protease
inhibitor HCV RNA monitoring Initial laboratory monitoring




Treatment naïve: Baseline and wks 4, 8, 12,
and 24 to assess for RGT
and futility
CBC: baseline and wks 4, 6, 8,











Assess for SVR 6 mos after
therapy is conpleted
Serum electrolytes, creatinine,
uric acid, LFTs, TSH: baseline
and wks 2, 4, 8, and 12c





dosed wks 0–12 for all
treatment regimens
Baseline and wks 4 and 12




LFTs, TSH: baseline and wks 2,
4, 8, and 12




Assess for SVR 6 mos after
therapy is completed
CBC, complete blood count; eRVR, extended rapid virologic response; LFTs, liver function tests; pegIFN, peginterferon; RBV, ribavirin; RGT,
response-guided therapy; TSH, thyroid-stimulating hormone.
a
Food increases the exposure to boceprevir by 65% compared with fasting state. Bioavailability is similar regardless of type of meal (high fat vs
low fat) and may be consumed before or after a meal.17
b
Telaprevir absorption is increased by 237% when taken with a standard fat meal (~500 calories, 20 g fat) compared with the fasting state.
Telaprevir should be administered within 30 minutes of a non-low-fat meal with at least 20 g fat content.16
c
Monitoring not part of package insert, but recommended by the authors. Laboratory monitoring should be performed at routine intervals
throughout therapy and more frequently if clinically indicated.
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Table 3







  Alfuzosin A1-adrenoreceptor antagonist Boceprevir and telaprevir Hypotension or cardiac arrhythmia
  Statins HMG CoA reductase inhibitors Boceprevir and telaprevir Myopathy including rhabdomyolysis
  Sildenafilb PDE5 inhibitors Boceprevir and telaprevir Vision changes, hypotension
  Midazolamc Sedatives Boceprevir and telaprevir Sedation/respiratory depression (oral
formulation)
  Pimozide Neuroleptic Boceprevir and telaprevir Cardiac arrhythmias
  Dihydroergotamine Ergot derivitives Boceprevir and telaprevir Vasospasm and ischemia
  Drosperinone Oral contraceptive Boceprevir Hyperkalemla
  Cisapride Gastrointestinal motility Boceprevir and telaprevir Cardiac arrhythmias
Potential for reduced protease
inhibitor activity
  Rifampin Antimycobacterial Boceprevir and telaprevir Significant reduction in protease plasma
concentration and may lead to viral
breakthrough
  St. John’s Wort Herbal medication Boceprevir and telaprevir
  Phenytoin Anticonvulsants Boceprevir
HMG CoA reductase inhibitor, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor; PDE5 inhibitors, phosphodiesterase 5 inhibitors.
NOTE. Please see package inserts for full listing of drug interactions and warnings.
a
Please see package inserts for full listing of drug interactions and warnings.
b
When used for pulmonary arterial hypertension. Please see package inserts for warnings and dosing for erectile dysfunction use.
c
Please see package inserts for warnings and monitoring for intravenous administration.
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Table 4
Adverse Events From Boceprevir and Telaprevir vs Standard of Care
Drug Adverse eventsa Treatment arm frequency SOC frequency Comment
Boceprevir6,9,15 Anemia 45%–50% 20%–30% Erythropoesis-stimulating agents allowed
Dysgeusia 35%–44% 11%–16%
Telaprevir7,8,10,16 Rash 56% 34% 6% discontinued telaprevir due to rash
Anemia 36% 17%
Anorectal symptomsa 29% 7%
SOC, standard of care; pegIFN, pegylated interferon; RBV, ribavirin.
a
Anorectal symptoms include hemorrhoids, anorectal discomfort, and anal pruritis.
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